BACKGROUND: Given the association of depression with poorer cardiac outcomes, an American Heart Association Science Advisory has advocated routine screening of cardiac patients for depression using the 2-item Patient Health Questionnaire (PHQ-2) "at a minimum." However, the prognostic value of the PHQ-2 among HF patients is unknown. METHODS AND RESULTS: We screened hospitalized HF patients (ejection fraction [EF] <40%) that staff suspected may be depressed with the PHQ-2, and then determined vital status at up to 12-months follow-up. At baseline, PHQ-2 depression screen-positive patients (PHQ-2+; n = 371), compared with PHQ-2 screen-negative patients (PHQ-2-; n = 100), were younger (65 vs 70 years) and more likely to report New York Heart Association (NYHA) functional class III/IV than class II symptoms (67% vs. 39%) and lower levels of physical and mental health-related quality of life (all P ≤ .002); they were similar in other characteristics (65% male, 26% mean EF). At 12 months, 20% of PHQ-2+ versus 8% of PHQ-2- patients had died (P = .007) and PHQ-2 status remained associated with both all-cause (hazard ratio [HR] 3.1, 95% confidence interval [CI] 1.4-6.7; P = .003) and cardiovascular (HR 2.7, 95% CI 1.1-6.6; P = .03) mortality even after adjustment for age, gender, EF, NYHA functional class, and a variety of other covariates. CONCLUSIONS: Among hospitalized HF patients, a positive PHQ-2 depression screen is associated with an elevated 12-month mortality risk. Copyright Â
BACKGROUND: Given the association of depression with poorer cardiac outcomes, an American Heart Association Science Advisory has advocated routine screening of cardiac patients for depression using the 2-item Patient Health Questionnaire (PHQ-2) "at a minimum." However, the prognostic value of the PHQ-2 among HF patients is unknown. METHODS AND RESULTS: We screened hospitalized HF patients (ejection fraction [EF] <40%) that staff suspected may be depressed with the PHQ-2, and then determined vital status at up to 12-months follow-up. At baseline, PHQ-2 depression screen-positive patients (PHQ-2+; n = 371), compared with PHQ-2 screen-negative patients (PHQ-2-; n = 100), were younger (65 vs 70 years) and more likely to report New York Heart Association (NYHA) functional class III/IV than class II symptoms (67% vs. 39%) and lower levels of physical and mental health-related quality of life (all P ≤ .002); they were similar in other characteristics (65% male, 26% mean EF). At 12 months, 20% of PHQ-2+ versus 8% of PHQ-2- patients had died (P = .007) and PHQ-2 status remained associated with both all-cause (hazard ratio [HR] 3.1, 95% confidence interval [CI] 1.4-6.7; P = .003) and cardiovascular (HR 2.7, 95% CI 1.1-6.6; P = .03) mortality even after adjustment for age, gender, EF, NYHA functional class, and a variety of other covariates. CONCLUSIONS: Among hospitalized HF patients, a positive PHQ-2 depression screen is associated with an elevated 12-month mortality risk. Copyright Â
Authors: Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-12-15 Impact factor: 29.690
Authors: W Jiang; J Alexander; E Christopher; M Kuchibhatla; L H Gaulden; M S Cuffe; M A Blazing; C Davenport; R M Califf; R R Krishnan; C M O'Connor Journal: Arch Intern Med Date: 2001 Aug 13-27
Authors: Kenneth E Freedland; Michael W Rich; Judith A Skala; Robert M Carney; Victor G Dávila-Román; Allan S Jaffe Journal: Psychosom Med Date: 2003 Jan-Feb Impact factor: 4.312
Authors: Mira-Lynn Chavanon; Thomas Meyer; Birgit Herbeck Belnap; Yan Huang; Kaleab Z Abebe; Bruce L Rollman; Christoph Herrmann-Lingen Journal: J Psychosom Res Date: 2019-08-14 Impact factor: 3.006
Authors: Bea Herbeck Belnap; Amy Anderson; Kaleab Z Abebe; Ravi Ramani; Matthew F Muldoon; Jordan F Karp; Bruce L Rollman Journal: Psychosom Med Date: 2019 Jul/Aug Impact factor: 4.312
Authors: Jeff C Huffman; Christopher M Celano; Scott R Beach; Shweta R Motiwala; James L Januzzi Journal: Cardiovasc Psychiatry Neurol Date: 2013-04-07
Authors: Chantal F Ski; David R Thompson; David L Hare; Andrew G Stewart; Roger Watson Journal: Health Qual Life Outcomes Date: 2012-11-23 Impact factor: 3.186
Authors: Marion Eisele; Eva Blozik; Stefan Störk; Jens-Martin Träder; Christoph Herrmann-Lingen; Martin Scherer Journal: BMC Fam Pract Date: 2013-11-27 Impact factor: 2.497